Cargando…
Low β(2)-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism
The underlying mechanisms responsible for the development of castration-resistant prostate cancer (CRPC) in patients who have undergone androgen deprivation therapy are not fully understood. This is the first study to address whether β(2)-adrenergic receptor (ADRB2)- mediated signaling may affect CR...
Autores principales: | Braadland, Peder Rustøen, Grytli, Helene Hartvedt, Ramberg, Håkon, Katz, Betina, Kellman, Ralf, Gauthier-Landry, Louis, Fazli, Ladan, Krobert, Kurt Allen, Wang, Wanzhong, Levy, Finn Olav, Bjartell, Anders, Berge, Viktor, Rennie, Paul S., Mellgren, Gunnar, Mælandsmo, Gunhild Mari, Svindland, Aud, Barbier, Olivier, Taskén, Kristin Austlid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811504/ https://www.ncbi.nlm.nih.gov/pubmed/26646591 |
Ejemplares similares
-
β-Adrenergic Receptor Signaling in Prostate Cancer
por: Braadland, Peder Rustøen, et al.
Publicado: (2015) -
Regulation of PBX3 expression by androgen and Let-7d in prostate cancer
por: Ramberg, Håkon, et al.
Publicado: (2011) -
Association of β-Blocker Use at Time of Radical Prostatectomy With Rate of Treatment for Prostate Cancer Recurrence
por: Sivanesan, Shivanthe, et al.
Publicado: (2022) -
Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer
por: Ramberg, Håkon, et al.
Publicado: (2021) -
Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
por: Guldvik, Ingrid Jenny, et al.
Publicado: (2022)